UBS Group
ARNA

UBS Group’s Arena Pharmaceuticals Inc ARNA Stock Holding History

UBS Group’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,800
Closed -$260K – 8313
2019
Q1 		$260K Buy
+5,800
New +$266K ﹤0.01% 4453
2016
Q1 		– Sell
-830
Closed -$16K – 8388
2015
Q4 		$16K Hold
830
– – ﹤0.01% 6967
2015
Q3 		$16K Sell
830
-250
-23% -$8.49K ﹤0.01% 6928
2015
Q2 		$50K Hold
1,080
– – ﹤0.01% 6014
2015
Q1 		$47K Sell
1,080
-15,520
-93% -$721K ﹤0.01% 6120
2014
Q4 		$576K Buy
+16,600
New +$674K ﹤0.01% 4067

UBS Group's ARNA Position: Q1 2022 in Review

UBS Group sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 119,798 shares — an estimated $11.1M sold.

UBS Group first reported a position in ARNA in Q4 2014 and held it in 29 quarters. The position peaked at $11.1M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

  • UBS Group reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
  • UBS Group sold 119,798 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $11.1M.
  • UBS Group first reported a position in Arena Pharmaceuticals Inc in Q4 2014 and held it in 29 quarters.
  • UBS Group's Arena Pharmaceuticals Inc position peaked at $11.1M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on UBS Group's 13F filing for Q1 2022, filed 16 May 2022.